Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 mass balance, absolute bioavailability, and pharmacokinetics study of E7727 in healthy volunteers aged 65 years or older
NL-OMON48473Phase 1Active, not recruiting
- Sponsor
- Astex Pharmaceuticals
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cedazuridine in myelodysplastic syndrome (MDS), sponsored by Astex Pharmaceuticals. Primary endpoint: Main excretion pathways of E7727. Started Feb 2019; status: active, not recruiting.
02
Drugs
cedazuridine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON48473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48473.